AIM Breakfasts

AIM BREAKFAST – 7th December 2016

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 990

Total number of AIM Companies trading: 963*
* As at 07 December 2016

Dish of the Day:

No AIM Joiners Today

Off the Menu:

No AIM Joiners Today

Set Menu ISDX Growth:

Total number of ISDX Growth Market Companies (Incl Susp): 84*

Total number of ISDX Growth Market Companies trading: 80*
* As at 07 December 2016

Dish of the Day:

African Potash (AFPO.L) has begun trading on ISDX 

Off the Menu:

No ISDX Growth Market Leavers Today

What’s Cooking in the IPO Kitchen?

Creo Medical group—Schedule 1 update.. £20m raise. Expected market cap £61.2m, admission expected 9 December.

ECSC—Schedule 1 from provider of cyber security services. Raising £5m. Vendor sale £0.8m. Target date 14 Dec. Expected market cap £15m.

RM Secured Direct Lending  –  The secured direct lending fund  intends to float on the Main Market on 15 December raising up to £100m


Breakfast Buffet

CAP-XX (CPX.L) 6.15p £16.62m

The specialist in supercapacitors  has achieved significant production cost savings on its supercapacitor solutions for both passenger & heavy vehicle applications.  The changes, which include the development of a proprietary electrode and the incorporation of new materials/processes, have resulted in significant reductions in the costs of materials and processing, while further enhancing the ‘ already industry leading performance.  Consequently, once full commercialisation has been achieved, CAP-XX now expects to see the truckStart module selling to truck OEMs and aftermarket chains for less than US$500, a significant reduction from the $1,000 price that was previously envisaged.


Autins Group (AUTG.L) 230.5p £50.94m

FYSep16 trading update from the  UK designer, manufacturer and supplier of acoustic and thermal insulation solutions for the automotive sector.   The Group continues to see progress with the integration of Autins’ Swedish and German divisions which became wholly owned subsidiaries at the August IPO.  Significant development has been made with Neptune, the lightweight, high performance material. Full production capability expected by year end.  Approved by 7 automotive OEMs. Gaining interest from outside the automotive sector. Overall, the year to date has been one of positive progress. Autins is on track to deliver further growth during 2017. Keeping close eye on input costs in light of weak sterling. No forecasts in the market.


CentralNic (CNIC.L) 46.75p £44.83m

The specialist in domain name and internet services, announced that the most popular new generic Top Level Domain ending .XYZ is one of the first domain endings to be accredited by the Chinese Ministry of Industry and Information Technology, allowing businesses and individuals in China to use .XYZ domain names to host their websites.  CentralNic, which is .XYZ’s exclusive distributor, worked closely with .XYZ to put in place a customised technology platform that has been approved by both the global internet regulator ICANN and China’s MIIT – succeeding in securing .XYZ a ranking among the first batch of non-Chinese “not-COM” domains approved for Chinese citizens. The web addresses will be available from the 16th December 2016.


Joules Group (JOUL.L) 202.5p £177.2m

The premium British lifestyle brand has provided a H1Nov trading update. Group revenue for the Period increased by 16.2% to £81.4m (H1 FY16: £70.1m), reflecting the brand’s increasing footprint, growing customer base and the strong performance of both new and core ranges across product categories.  Gross margin up 100 bips. “Despite the uncertain macro-economic outlook. We have seen strong growth in our wholesale order book for Spring/Summer 17 and we are well positioned for the Christmas trading period.”  FYmay17E revenues of £151.1m and PBT of £9m. 22.7x PE. 1.1% yield.


LiDCO Group (LID.L) 7p £13.59m

The hemodynamic monitoring company  has announced a conditional placing of £3m at 6p, a 14% discount to yesterday’s close. LiDCO intends to use the net proceeds from the Placing and Subscriptions to accelerate growth into the US market, which the Directors believe has the most significant growth opportunity at present, as well as growing sales through additional resource in other international markets, whilst maintaining its market leading status in the UK .


Private & Commercial Finance Group (PCF.L) 29p £49.34m

The finance house announced that its application for a Banking Licence has been successful and has been approved by the Prudential Regulatory Authority  and the Financial Conduct Authority. PCF is now authorised with restrictions as a bank and enters into a mobilisation period of up to 12 months. This is on a restricted basis until new policies and procedures are in place. PCF is well advanced in this process.  Expected to take its first deposits in summer 2017. Initially will support SME asset and consumer motor finance activities and then assess product expansion.


Be Heard Group (BHRD.L) 3.4p £23.15m

The digital marketing services group, announced the acquisition of Kameleon Worldwide Limited, the award-winning content marketing agency.  For the financial year ended 31 Dec 2015 Kameleon achieved adjusted EBITDA of £0.53m on gross revenues of £2.43m. In 2016, it is expected to generate gross revenues of £3.89m, representing 60% annual growth, with adjusted EBITDA of £0.785m.  Initial consideration of £4m. Total deal capped at £10m. Mixed cash and shares deal.

FYDec16E rev £9.1m and PBT of £0.7m


United Cacao (CHOC.L) 122.5p £23.49m

The cacao plantation company based in Peru, has announced that the General Directorate for Agricultural Environmental Affairs (DGAAA) – a division of the Peruvian Ministry of Agriculture – has approved the Company’s soil study report that was originally submitted on 30 December 2014. The DGAAA is the relevant regulatory authority for agricultural land titles in Peru.


Frontier IP Group (FIPP.L) 32.5p £10m

The specialist in  the commercialisation of intellectual property, has received a 20% stake in Tarsis Technology Limited (Tarsis), the Group’s third spin-out from the Department of Chemical Engineering and Biotechnology at the University of CambridgeTarsis plans to develop and commercialise technology that allows slower and more controlled delivery of drugs using metal-organic frameworks. The pharmaceutical industry has demonstrated early interest in the technology.


Kromek Group (KMK.L) 353.5p £38.4m

HYOct16 results from  radiation detection technology company focusing on the medical, security and nuclear markets.  Revenue up 19% to £3.8m. Loss before tax reduced by 41% to £1.8m. Cash and cash equivalents at 31 October 2016 were £3.8m vs £7.5m. The Group already has significant visibility over revenue accounting for more than 85% of market expectations for full year 2016/17.  FYAPR17E revs of £8.9m and pre-tax loss of £3.7m.


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email with “unsubscribe me”.